Description of sp. nov. (Hymenoptera, Pteromalidae), with notes on the fauna of Asaphesinae and Pteromalidae (Hymenoptera, Chalcidoidea) collected from foliage of (L.) H. Karst. in Bulgaria.

Background: Westwood, 1833 consists of about 135 valid species worldwide. After the fundamental monograph of Graham (1969), 12 species have been described from continental Europe and three species have been described from the Canary Islands and Malta. Amongst them, one species, Askew, 1994, has been synonymised under (Mercet, 1923).

Review of the Palaearctic species of Bouček, 1956 (Chalcidoidea, Pteromalidae), with descriptions of the eight new species.

Palaearctic species of the genus Bouček, 1956 are reviewed. Twelve Palaearctic species are recognized based on females, of which eight new species are described: Tselikh, Lee & Ku, (Republic of Korea), Tselikh, Lee & Ku, (Republic of Korea), Tselikh, Haas & Ku, (Republic of Korea, Sweden), Tselikh, Lee & Ku, (Republic of Korea), Tselikh, Lee & Ku, (Republic of Korea), Tselikh, Lee & Ku, (Republic of Korea), Tselikh, Haas & Ku, (Germany, Japan, Sweden), and Tselikh, Haas & Ku, (Russia, Republic of Korea, Sweden). The female of Bouček, 1956 is described for the first time.

Highlighting overlooked biodiversity through online platforms: The "Chalcid Wasps of Cyprus" website.

Biodiversity data platforms including databases, websites and data repositories underpin conservation efforts by collecting spatiotemporal data of discovered native and alien species and maps of their distributions. Chalcid wasps (Hymenoptera, Chalcidoidea) are one of the most diverse insect groups estimated to include half a million species. Being mostly parasitoids of other arthropods, they have been successfully used as biological control agents against serious agricultural pests worldwide.

Bevacizumab-Based Therapies in Malignant Tumors-Real-World Data on Effectiveness, Safety, and Cost.

Unlabelled: Overall, it is estimated that more than 3,500,000 patients have received Bevacizumab as part of systemic oncologic treatment. Bevacizumab and its biosimilars are currently marketed in over 130 countries. Given the wide usage of Bevacizumab in current oncological practice, it is very important to compare the "real-world" results to those obtained in controlled clinical trials.